Anchored Drug Delivery™

eye 4a.jpg

AnkyRx™ Revolutionary Drug Delivery

AnkyrBio, LLC is a preclinical biotech drug delivery company that improves the efficacy of therapies in wet epithelial areas through its anchoring technology, called AnkyRx™. AnkyRx™ can be linked with most biologics and potentially small molecules, improving the effective treatment through extended retention at the treatment site. While initially focusing on the ocular surface, other prospective wet tissue areas include the oral cavity, joints, digestive tract, bladder, urinary tract, and female reproductive system. Similar applications in animal health are possible.

Adherent Topical Therapies

Therapies directed at wet surfaces are prone to washout, substantially reducing treatment effectiveness. AnkyrBio offers a novel solution to this problem; AnkyRx™ binds therapeutics to cellular and biological surfaces. These anchors hold the therapeutic at its targeted location for hours or days as compared to one to two minutes on the cornea without the anchor.

AnkyrBio Transforms Eye Therapies

The tear layer on the eye is replaced every 1-2 minutes eliminating the long lasting effect of unanchored therapies. Washout is often countered by increasing the dose of the active ingredient and/or increasing application frequency. These methods increase side effects, limit efficacy, and reduce patient compliance. Coupling AnkyRx™ with effective therapies delivers prolonged retention on a wet biological surface enabling both reduced dosages and reduced frequency of application.

AnkyrBio has identified other potential target areas including oral, joint, digestive, urinary, female reproductive system where regular fluid and mucus adversely affects the benefit of unbound therapies.